Abstract
Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have